immune regeneration and reversal of age-related immune decline
Very little changed between January 28, 2016 and January 4, 2017. Intervene Immune kept the same core claim: age-related immune decline is not just something to watch sadly from across the room, but something that can be reversed through immune regeneration. In both snapshots, the thymus is the star of the show because it shrinks with age and is presented as regenerable. The surrounding promises also stayed basically fixed. Both versions tie thymic regeneration to a broad set of ambitions: reversing immunosenescence, preventing transplant rejection, and reversing autoimmune disorders. That is a wide spread of claims for such a short homepage pitch, and there is no sign here of narrowing, retreat, or a more careful framing. So the belief evolution is mostly continuity, not revision. If anything shifted, it was rhetorical polish rather than substance. Evidence is thin because these are only two Wayback snapshots from consecutive years, both saying nearly the same thing. That is enough to show message stability. It is not enough to show whether the company changed its evidence base, clinical confidence, or actual program direction behind the scenes.